Seres Therapeutics, Inc.

Good day and thank you for standing by. Welcome to the Q2 2022 Ceres Therapeutics, Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise. Should you require any assistance, please press star zero on your telephone keypad and an operator will assist you. During today's call, there will be a question and answer session. If you would like to ask a question during this time, please press star one on your telephone keypad. I will now turn the conference over to Dr. Carlo Tanzi, Investor Relations. Please go ahead.

Thank you and good morning. Our press release for the company's second quarter 2022 financial results and a business update became available at 7 a.m. Eastern Time this morning and can be found on the Investors and Use section of the company's website. I'd like to remind you that we'll be making forward-looking statements, including the potential approval of CR-109 and its status as a first-in-class therapeutic, the timing of a BLA filing and potential product launch, the market for SEER-109, the ultimate safety and efficacy data for our products, the use of cash to fund operations, and other statements which are not historical fact. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the risk factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so. On today's call, with prepared remarks, I'm joined by Eric Schaaf, series president and CEO, David Arkowitz, CFO, Dr. Lisa Valmolke, chief medical officer, and Dr. Matthew Henn, chief scientific officer. Additional members of our management team will also be available during the Q&A. And with that, I'll pass the call over to Eric.

Thank you, Carlo, and good morning, everyone.